The method's potential for retrospective urinary screening of Z-drug exposure in forensic and clinical toxicology is supported, and its potential for retrospective urinary screening of Z-drug exposure in forensic and clinical toxicology is supported.
Abstract
Zolpidem (Z1) and zopiclone (Z2) are widely prescribed for insomnia; but their misuse in drug-facilitated crimes presents significant forensic and clinical challenges. This study aimed to develop and validate a simple and sensitive LC-MS/MS method, coupled with dispersive liquid-liquid microextraction (DLLME), for the simultaneous determination of Z1, Z2, and 18 phase I and phase II metabolites (20 species) in human urine. DLLME employed 1 mL of dichloromethane as extractant and 2 mL of acetonitrile as disperser per 2 mL of urine, reducing halogenated-solvent use compared with conventional liquid-liquid extraction. Chromatographic separation was achieved on a HyPURITY C18 column with water-acetonitrile (70:30, v/v) containing 0.2% formic acid. Z1 and Z2 were validated according to ICH guidelines over 0.1-200 ng/mL, showing linearity (R2 > 0.999), accuracy (96.29%-99.56%), precision (RSD ≤ 3.12%), and recovery (96.12%-98.74%). Because authentic metabolite standards were unavailable, metabolite concentrations were estimated using parent-drug calibration curves and are considered semi-quantitative. In five healthy volunteers, hydroxylated and carboxylated metabolites peaked at 2-12 h and remained detectable up to 84 h. These findings support the method's potential for retrospective urinary screening of Z-drug exposure in forensic and clinical toxicology.
The clinical development of a sustained-release amlexanox formulation with reduced dosing frequency and improved patient compliance is supported and support the clinical development of a sustained-release amlexanox formulation with reduced dosing frequency and improved patient compliance.
A sensitive and validated liquid chromatography-tandem mass spectrometry method was developed for the simultaneous quantification of the anti-COVID-19 agents molnupiravir, its active metabolite N-hydroxycytidine (NHC), and baricitinib in human plasma, and met the acceptance criteria.
Fatma H. Ghazy, Ramzia I. El-Bagary, Samar H. Fahim et al.· Bioanalysis· 0 citations
A sensitive and reliable ultra-high performance liquid chromatography-tandem mass spectrometry (LC-MS/MS) method was developed and validated for the quantification of ibuprofen in plasma to investigate the pharmacokinetics of ibuprofen after oral administration of ibuprofen sustained-release capsules.
Mei-Ah Yang, Kui He, Yu-Jie Mo et al.· Acta Chromatographica· 0 citations
In vivo pharmacokinetic studies confirmed that the UPLC-MS/MS method could be successfully used for the analysis of bosutinib after oral administration of 50 mg/kg in rats, and provides a potential reference for the clinical investigation of bosutinib.
Pei-Qi Wang, Yan Chen, Jun Wu et al.· Chemico-Biological Interacti...· 1 citation
A sensitive, reliable, and rapid UPLC–MS/MS method was developed and validated for the simultaneous determination of ensartinib and M465 in rat plasma and applied to a rat pharmacokinetic study and provides useful analytical support for further preclinical investigations of ensartinib and its major metabolite.
Shi-Qi Jiang, Yan Chen, Lu Cao et al.· Drug Design, Development and...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.